Literature DB >> 25540367

The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.

Rosemary J Tierney1, Jasdeep Nagra2, Martin Rowe2, Andrew I Bell2, Alan B Rickinson2.   

Abstract

UNLABELLED: Epstein-Barr virus (EBV) infection of B cells leads to the sequential activation of two viral promoters, Wp and Cp, resulting in the expression of six EBV nuclear antigens (EBNAs) and the viral Bcl2 homologue BHRF1. The viral transactivator EBNA2 is required for this switch from Wp to Cp usage during the initial stages of infection. EBNA2-dependent Cp transcription is mediated by the EBNA2 response element (E2RE), a region that contains at least two binding sites for cellular factors; one of these sites, CBF1, interacts with RBP-JK, which then recruits EBNA2 to the transcription initiation complex. Here we demonstrate that the B cell-specific transcription factor BSAP/Pax5 binds to a second site, CBF2, in the E2RE. Deletion of the E2RE in the context of a recombinant virus greatly diminished levels of Cp-initiated transcripts during the initial stages of infection but did not affect the levels of Wp-initiated transcripts or EBNA mRNAs. Consistent with this finding, viruses deleted for the E2RE were not markedly impaired in their ability to induce B cell transformation in vitro. In contrast, a larger deletion of the entire Cp region did reduce EBNA mRNA levels early after infection and subsequently almost completely ablated lymphoblastoid cell line (LCL) outgrowth. Notably, however, rare LCLs could be established following infection with Cp-deleted viruses, and these were indistinguishable from wild-type-derived LCLs in terms of steady-state EBV gene transcription. These data indicate that, unlike Wp, Cp is dispensable for the virus' growth-transforming activity. IMPORTANCE: Epstein-Barr virus (EBV), a B lymphotropic herpesvirus etiologically linked to several B cell malignancies, efficiently induces B cell proliferation leading to the outgrowth of lymphoblastoid cell lines (LCLs). The initial stages of this growth-transforming infection are characterized by the sequential activation of two viral promoters, Wp and Cp, both of which appear to be preferentially active in target B cells. In this work, we have investigated the importance of Cp activity in initiating B cell proliferation and maintaining LCL growth. Using recombinant viruses, we demonstrate that while Cp is not essential for LCL outgrowth in vitro, it enhances transformation efficiency by >100-fold. We also show that Cp, like Wp, interacts with the B cell-specific activator protein BSAP/Pax5. We suggest that EBV has evolved this two-promoter system to ensure efficient colonization of the host B cell system in vivo.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25540367      PMCID: PMC4325715          DOI: 10.1128/JVI.03300-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.

Authors:  E M Fuentes-Pananá; R Peng; G Brewer; J Tan; P D Ling
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.

Authors:  A Sjöblom; A Nerstedt; A Jansson; L Rymo
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

3.  The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein.

Authors:  S R Grossman; E Johannsen; X Tong; R Yalamanchili; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

4.  The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5.

Authors:  R Tierney; H Kirby; J Nagra; A Rickinson; A Bell
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2.

Authors:  J J Hsieh; S D Hayward
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

6.  Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa.

Authors:  T Henkel; P D Ling; S D Hayward; M G Peterson
Journal:  Science       Date:  1994-07-01       Impact factor: 47.728

7.  Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP.

Authors:  P Urbánek; Z Q Wang; I Fetka; E F Wagner; M Busslinger
Journal:  Cell       Date:  1994-12-02       Impact factor: 41.582

Review 8.  Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data.

Authors:  Aaron Arvey; Italo Tempera; Paul M Lieberman
Journal:  Viruses       Date:  2013-04-02       Impact factor: 5.048

9.  The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements.

Authors:  L Waltzer; F Logeat; C Brou; A Israel; A Sergeant; E Manet
Journal:  EMBO J       Date:  1994-12-01       Impact factor: 11.598

10.  RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus.

Authors:  Richard D Palermo; Helen M Webb; Michelle J West
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

View more
  1 in total

1.  Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells.

Authors:  Leah Fitzsimmons; Andrew J Boyce; Wenbin Wei; Catherine Chang; Deborah Croom-Carter; Rosemary J Tierney; Marco J Herold; Andrew I Bell; Andreas Strasser; Gemma L Kelly; Martin Rowe
Journal:  Cell Death Differ       Date:  2017-09-29       Impact factor: 15.828

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.